Fulgent Genetics Inc (FLGT) - Company Annual Revenue

The digitalization of reporting and ESG standards are optimizing expenses for Fulgent Genetics, Inc. (FLGT), as confirmed by the general GURU.Markets platform chart: the company's aggregated sales have reached 0.33. This price action is based on the implementation of AI in oncology diagnostics, although external risks of reagent supply chain disruptions create certain volatility. The current trend demonstrates business scaling, balancing revenue growth against the limits of operational efficiency.

Fulgent (FLGT): Company Revenue from 07/04/2022 to 11/15/2026

Comprehensive metric breakdowns and analytics for fulgentgenetics.com (FLGT)

- market value and analyst target forecast:

Market Chart Fulgent Genetics, Inc.|FLGT - Analyst Consensus Forecast

- market capitalization indicators:

Market Valuation Fulgent|FLGT - Real Price to Acquire Entire Company

- business book valuation details:

Book Value per Share Fulgent Genetics|FLGT - Company Book Value|Market Value to Book Value Ratio fulgentgenetics.com|FLGT - Company Total Assets

- debt obligations and liquidity statistics:

- net income and valuation ratios data:

FLGT - Net Profit|Projected Net Profit Fulgent Genetics, Inc.|FLGT - P/E Multiple|Projected Price to Earnings Ratio Fulgent Genetics Inc|FLGT - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Fulgent Genetics Inc|FLGT - Operating profit EBITDA|Net earnings per one share for the last twelve months Fulgent Genetics|FLGT - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months fulgentgenetics.com|FLGT - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Fulgent Genetics, Inc.

- sales volume and revenue indicators:

FLGT - Revenue and Sales Volume|Company Future Sales Volume fulgentgenetics.com|FLGT - Price-to-Revenue Ratio|Market Cap to Expected Sales Ratio Fulgent|FLGT - Revenue Growth YoY (Last 12 Months)

Comprehensive company analysis:Fulgent Genetics FLGT

Mass-produced product of Fulgent Genetics, Inc.

For the Fulgent Genetics, Inc. (FLGT) molecular testing ecosystem, revenue serves as a key indicator of the commercial demand for high-precision diagnostic services. This metric captures daily cash inflows, allowing for the verification of actual demand for genomic research. By analyzing corporate sales dynamics, an investor can identify reporting anomalies and the risk of overpaying for the asset. Stable growth confirms the platform's scaling within the medical field, while sharp declines signal a potential threat to liquidity.

Competing companies